New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:49 EDTABMDAbiomed shares overvalued, says Northland Securities
Northland believes Abiomed utilization rates for Impella are going down on both the ImpellaCP and Impella 2.5. The firm said Abiomed's story is now dependent on new site add-ons where utilization rates haven moved and sees risk to shares. The firm rates Abiomed an Underperform with a $14 price target.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:10 EDTABMDAbiomed narrows FY15 revenue guidance to $209M-$212M from $205M-$212M
Subscribe for More Information
07:09 EDTABMDAbiomed reports Q2 EPS 9c, consensus 2c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use